Introduction: Illumina’s acquisition of Grail blocked by the EU Commission In a landmark decision on 6 September 2022, the Commission prohibited under the Merger Regulation the completed acquisition by Illumina, a U.S. company specializing in genomic sequencing, of Grail, a U.S. based start-up known for developing early cancer detection tests.